BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
February 24, 2022 7:30 AM ESTSecured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBios financial runway into 2024
Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data readout anticipated in second half of 2022
Launched clinical collaboration with Amgen to study BBP-398, a potentially best-in-class SHP2 inhibitor, in combination with LUMAKRAS® (sotorasib) in advanced solid tumors with the KRAS G12C mutation
Established strategic collaboration with Helsinn Group to co-develop and co-commercialize BridgeBios novel GPX4 inhibitor in multiple cancer tumor types
Reported Month 12 topline results from... More
